US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CERo Therapeutics Holdings, Inc.

9.46

+0.23002.49%

Pre-market: 9.520.0600+0.63%04:36 EDT

Volume:90.89K

Turnover:858.13K

Market Cap:4.88M

PE:0.00

High:9.73

Open:9.10

Low:9.10

Close:9.23

Loading ...

Overview Company News Filings

CERo Therapeutics Cut to Hold From Buy by D. Boral Capital

Cero Therapeutics Holdings, Inc. Doses First Patient With Cer-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and Is Advancing Through Protocol-Defined Evaluations

THOMSON REUTERS

Cero Therapeutics Holdings Inc. Conducted Annual Stockholders Meeting

CERo Therapeutics Initiated at Buy by Maxim Group

Cero Therapeutics initiated with a Buy at Maxim

BRIEF-Cero Therapeutics Announces Tristar Centennial Medical Center As A Clinical Trial Site For Its Phase 1 Clinical Trial Of Cer-1236 In Acute Myeloid Leukemia

Cero Therapeutics Holdings, Inc. Announces Tristar Centennial Medical Center as a Clinical Trial Site for Its Phase 1 Clinical Trial of Cer-1236 in Acute Myeloid Leukemia

THOMSON REUTERS

CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

Gold Gains 1%; Bristol Myers Squibb Posts Upbeat Results

Dow Jumps Over 200 Points; PepsiCo Cuts Earnings Outlook

Cero Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for Its Phase 1 Clinical Trial of Cer-1236 in Acute Myeloid Leukemia

THOMSON REUTERS

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Initiated at Buy by D. Boral Capital

Cero Therapeutics, Inc. Announces up to $8 Million Series D Financing

THOMSON REUTERS

CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing

BRIEF-Cero Therapeutics Announces Critical Patent Application Allowances From The U.S. Patent Office

Cero Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances From the U.S. Patent Office Covering Company’s Lead Compound Cer-1236

THOMSON REUTERS

CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company’s Lead Compound CER-1236

CERo Gets FDA Clearance for CER-1236 Trial in Solid Tumors

MT Newswires Live

Cero Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound Cer-1236 in Solid Tumors

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CERO/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CERO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CERO\",,,,,undefined,":{"symbol":"CERO","market":"US","secType":"STK","nameCN":"CERo Therapeutics Holdings, Inc.","latestPrice":9.46,"timestamp":1751486400000,"preClose":9.23,"halted":0,"volume":90891,"hourTrading":{"tag":"盘前","latestPrice":9.52,"preClose":9.46,"latestTime":"04:36 EDT","volume":30,"amount":285.59999999999997,"timestamp":1751531802013},"delay":0,"floatShares":317500,"shares":516100,"eps":-11135.544,"marketStatus":"Pre-Mkt","change":0.23,"latestTime":"07-03 05:54:19 EDT","open":9.1,"high":9.73,"low":9.1,"amount":858134.4699779999,"amplitude":0.068256,"askPrice":9.55,"askSize":5,"bidPrice":9.09,"bidSize":25,"shortable":3,"etf":0,"ttmEps":-11135.544,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1751549400000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":9.46,"preHourTrading":{"tag":"盘前","latestPrice":9.52,"preClose":9.46,"latestTime":"04:36 EDT","volume":30,"amount":285.59999999999997,"timestamp":1751531802013},"postHourTrading":{"tag":"盘后","latestPrice":9.36,"preClose":9.46,"latestTime":"19:59 EDT","volume":310,"amount":2892.8625,"timestamp":1751500790017},"volumeRatio":0.3843047747239887},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CERO\",,,,,undefined,":{"symbol":"CERO","floatShares":317500,"roa":"-122.86%","roe":"--","lyrEps":-15538.9768,"volumeRatio":0.3843047747239887,"shares":516100,"dividePrice":0,"high":9.73,"amplitude":0.068256,"preClose":9.23,"low":9.1,"week52Low":6.71,"pbRate":"-1.77","week52High":895.4,"institutionHeld":0,"latestPrice":9.46,"committee":0.666667,"eps":-11135.544,"divideRate":0,"volume":90891,"delay":0,"ttmEps":-11135.544,"open":9.1,"prevYearClose":120,"prevWeekClose":9.55,"prevMonthClose":9.63,"prevQuarterClose":9.63,"fiveDayClose":11.19,"twentyDayClose":9.38,"sixtyDayClose":14.302},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CERO\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2539222122","title":"CERo Therapeutics Cut to Hold From Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2539222122","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539222122?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:35","pubTimestamp":1748608500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CERO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 30, 2025 08:35 ET (12:35 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","BK4139","CERO","LENZ"],"gpt_icon":0},{"id":"2539722420","title":"Cero Therapeutics Holdings, Inc. Doses First Patient With Cer-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and Is Advancing Through Protocol-Defined Evaluations","url":"https://stock-news.laohu8.com/highlight/detail?id=2539722420","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539722420?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:15","pubTimestamp":1748607300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nTUA3KVDL3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2539296700","title":"Cero Therapeutics Holdings Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2539296700","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539296700?lang=en_us&edition=fundamental","pubTime":"2025-05-30 05:11","pubTimestamp":1748553064,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Holdings Inc. held its 2025 Annual Meeting of Stockholders on May 29, 2025. Stockholders approved an amendment to increase the number of shares available under the 2024 Equity Incentive Plan by an additional 2,000,000 shares. Additionally, the issuance of shares of Common Stock in accordance with Nasdaq Listing Rule 5635, upon the exercise of warrants issued in a registered direct offering in February 2025, was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 29, 2025, and is","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDLkq2RJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2536124636","title":"CERo Therapeutics Initiated at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2536124636","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536124636?lang=en_us&edition=fundamental","pubTime":"2025-05-20 00:02","pubTimestamp":1747670520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CERO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 19, 2025 12:02 ET (16:02 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","LENZ","CERO","BK4139"],"gpt_icon":0},{"id":"2536689427","title":"Cero Therapeutics initiated with a Buy at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2536689427","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536689427?lang=en_us&edition=fundamental","pubTime":"2025-05-19 19:45","pubTimestamp":1747655110,"startTime":"0","endTime":"0","summary":"Maxim analyst Jason McCarthy initiated coverage of Cero Therapeutics (CERO) with a Buy rating and $3 price target Published first on TheFly – the u...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cero-therapeutics-initiated-with-a-buy-at-maxim?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cero-therapeutics-initiated-with-a-buy-at-maxim?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","LENZ","BK4007","CERO"],"gpt_icon":0},{"id":"2531503125","title":"BRIEF-Cero Therapeutics Announces Tristar Centennial Medical Center As A Clinical Trial Site For Its Phase 1 Clinical Trial Of Cer-1236 In Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2531503125","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531503125?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:19","pubTimestamp":1746015542,"startTime":"0","endTime":"0","summary":"BRIEF-Cero Therapeutics Announces Tristar Centennial Medical Center As A Clinical Trial Site For Its Phase 1 Clinical Trial Of Cer-1236 In Acute Myeloid LeukemiaApril 30 (Reuters) - CERo Therapeutics ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUA2ZQPTB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2531031916","title":"Cero Therapeutics Holdings, Inc. Announces Tristar Centennial Medical Center as a Clinical Trial Site for Its Phase 1 Clinical Trial of Cer-1236 in Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2531031916","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531031916?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:15","pubTimestamp":1746015300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUA2ZQPTB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2531203126","title":"CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2531203126","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531203126?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:15","pubTimestamp":1746015300,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., April 30, 2025  -- CERo Therapeutics Holdings, Inc.,   an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that TriStar Centennial Medical Center, through Sarah Cannon Research Institute , in Nashville, Tennessee, is a clinical trial site for the Company’s Phase 1 clinical of CER-1236. Collaborating with SCRI to advance cancer research, TriStar Centennial offers innovative clinical research trials for various disease indications. The trial is focused on patients with acute myeloid leukemia , and patient enrollment is underway, with expected dosing of the first patient during the first half of 2025.CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-holdings-inc-announces-121500799.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CERO","CEROW","CR","BK4181","ORR","BK4139","BK4161","BK4218","PK"],"gpt_icon":0},{"id":"2530950048","title":"Gold Gains 1%; Bristol Myers Squibb Posts Upbeat Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2530950048","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530950048?lang=en_us&edition=fundamental","pubTime":"2025-04-25 01:11","pubTimestamp":1745514680,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/04/44989183/gold-gains-1-bristol-myers-squibb-posts-upbeat-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QLD","LU0965508806.USD","LU0980610538.SGD","LU1880383366.USD","QID","LU0306806265.USD","USJW.SI","CYH","LU1670711040.USD","TSYW.SI","LU1037948897.HKD","NVIW.SI","LU0130518102.USD","LU0320765489.SGD","LU0477156953.USD","TQQQ","BK4139","LU1934455863.HKD","MYE","LU1585245621.USD","MNQmain",".IXIC","LU1868836914.USD","LU0130103400.USD","LU0070302665.USD","ASGN","FI","LU1201861165.SGD","BK4007","BMY","LU2125154778.USD","LU0175139822.USD","PSQ","LU0985481810.HKD","LU0648000940.SGD","LU0096364046.USD","LU0203347892.USD","CERO","LU2108987350.USD","TMC","USAW.SI","LU1291159041.SGD","SQQQ","NQmain","LU0868494617.USD","LU0061475181.USD","LU1261432733.SGD","BK4204"],"gpt_icon":1},{"id":"2529958771","title":"Dow Jumps Over 200 Points; PepsiCo Cuts Earnings Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2529958771","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529958771?lang=en_us&edition=fundamental","pubTime":"2025-04-24 23:06","pubTimestamp":1745507212,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/04/44984387/dow-jumps-over-200-points-pepsico-cuts-earnings-outlook","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCOM","PEP","XELB","NCNA","CEP","JZXN","CERO","GNLN"],"gpt_icon":0},{"id":"2529899399","title":"Cero Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for Its Phase 1 Clinical Trial of Cer-1236 in Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2529899399","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529899399?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:15","pubTimestamp":1745496900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nTUA8SFJZG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2529818619","title":"CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2529818619","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529818619?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:15","pubTimestamp":1745496900,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANSCISCO, Calif, April 24, 2025  -- CERo Therapeutics Holdings, Inc.,   an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that Sarah Cannon Research Institute  at Colorado Blood Cancer Institute  in Denver, Colorado will be a key clinical trial site for the Company’s Phase 1 clinical trial of CER-1236. Partnering with SCRI to advance cancer research, CBCI is the region’s leader in blood cancer care and serves a seven-state region. The trial is focused on patients with acute myeloid leukemia , and patient enrollment is underway with first dosing of the initial cohort of patients expected by June.CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and ad","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-holdings-inc-announces-121500646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PK","BK4161","CERO","BK4139","CEROW","BK4181","ORR","CR","BK4218"],"gpt_icon":0},{"id":"2529573584","title":"CERo Therapeutics Initiated at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2529573584","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529573584?lang=en_us&edition=fundamental","pubTime":"2025-04-22 22:07","pubTimestamp":1745330820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CERO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 22, 2025 10:07 ET (14:07 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CERO","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2529057863","title":"Cero Therapeutics, Inc. Announces up to $8 Million Series D Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2529057863","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529057863?lang=en_us&edition=fundamental","pubTime":"2025-04-22 20:15","pubTimestamp":1745324100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA98QTMY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2529205306","title":"CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2529205306","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529205306?lang=en_us&edition=fundamental","pubTime":"2025-04-22 20:15","pubTimestamp":1745324100,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif, April 22, 2025  -- CERo Therapeutics Holdings, Inc.  , an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that it has entered into a securities purchase agreement for the issuance and sale of securities under a new convertible preferred stock transaction.The gross proceeds to CERo from the offering are expected to be up to $8 million, including $5 million expected to be received through the investment of securities at the first closing, and up to $3 million of cash that may be funded at one or more additional closings, at the election of the investors. CERo intends to use the net proceeds from the offering to take advantage of the two recent FDA IND allowances in liquid and solid tumors and complete the previously announced site activation at MDACC, as well as bring other sites online quickly. The proceeds will also help to address current Nasdaq deficienci","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-inc-announces-8-121500993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","CEROW","LENZ","CERO","BK4139"],"gpt_icon":0},{"id":"2526459595","title":"BRIEF-Cero Therapeutics Announces Critical Patent Application Allowances From The U.S. Patent Office","url":"https://stock-news.laohu8.com/highlight/detail?id=2526459595","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526459595?lang=en_us&edition=fundamental","pubTime":"2025-04-10 22:18","pubTimestamp":1744294701,"startTime":"0","endTime":"0","summary":"BRIEF-Cero Therapeutics Announces Critical Patent Application Allowances From The U.S. Patent OfficeApril 10 (Reuters) - CERo Therapeutics Holdings Inc CERO.O:CERO THERAPEUTICS HOLDINGS, INC. ANNOUNCE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QO149:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2526656515","title":"Cero Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances From the U.S. Patent Office Covering Company’s Lead Compound Cer-1236","url":"https://stock-news.laohu8.com/highlight/detail?id=2526656515","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526656515?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:15","pubTimestamp":1744287312,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QO149:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2526256565","title":"CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company’s Lead Compound CER-1236","url":"https://stock-news.laohu8.com/highlight/detail?id=2526256565","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526256565?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:15","pubTimestamp":1744287300,"startTime":"0","endTime":"0","summary":"Results in 17 Issued and Allowed Patent Applications Internationally with Nine Total Patent Families. Patent Application No. 17/040,472, titled, “CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF,” was allowed on March 13, 2025 and provides coverage for composition of matter and methods of use coverage for the Company’s lead compound, CER-1236. The allowed claims encompass the combination of a phosphatidylserine-targeting CD4+ CER-T cell with a CD8+ CAR-T cell or a CD8+ recombinant TCR-T cell, and their use to treat cancer. This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is desig","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-holdings-inc-announces-121500762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CEROW","CERO"],"gpt_icon":0},{"id":"2523929967","title":"CERo Gets FDA Clearance for CER-1236 Trial in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2523929967","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523929967?lang=en_us&edition=fundamental","pubTime":"2025-03-31 23:20","pubTimestamp":1743434414,"startTime":"0","endTime":"0","summary":"CERo Therapeutics  said Monday the US Food and Drug Administration has cleared its second investigational new drug application for CER-1236 for a phase 1 trial in advanced solid tumors, specifically non-small cell lung cancer and ovarian cancer.\"Following the launch of our AML trial, we are now starting a second clinical study of CER-1236 to evaluate its potential in solid tumors,\" said Chief Medical Officer Robert Sikorski. AML refers to acute myeloid leukemia.The company said that recent results showed that CER-1236 treated ovarian cancer cells and didn't generate toxicity in mice.Price: 0.76, Change: +0.01, Percent Change: +1.20","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2523946328","title":"Cero Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound Cer-1236 in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2523946328","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523946328?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:15","pubTimestamp":1743423309,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QE0XS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CERO"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":60,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CERO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-06-13","symbol":"CERO","defaultRemindTime":1749821400000,"type":"split","dateTimestamp":1749787200000,"forFactor":20,"toFactor":1,"ratio":20},{"market":"US","date":"2025-01-08","symbol":"CERO","defaultRemindTime":1736346600000,"type":"split","dateTimestamp":1736312400000,"forFactor":100,"toFactor":1,"ratio":100},{"market":"US","date":"2024-02-15","symbol":"CERO","reason":null,"defaultRemindTime":1708007400000,"announcedDate":"2024-02-14","type":"delisting","dateTimestamp":1707973200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CERO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CERO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1750737600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CERO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CERO","date":"2025-07-01","current":-0.334649,"percent":0.857585,"low":-23.40166,"twenty":-6.816356,"median":-1.733515,"eighty":-0.475509,"high":-0.137942,"avg":-3.931905,"sd":4.868416,"marketCap":3718171},"quantilePoints":[{"date":"2024-02-23","current":-14.247617,"twenty":-20.956561,"median":-17.613942,"eighty":-14.944588,"marketCap":35849112},{"date":"2024-03-01","current":-17.506812,"twenty":-18.431546,"median":-15.409236,"eighty":-15.153206,"marketCap":44049729},{"date":"2024-03-08","current":-18.247371,"twenty":-17.820809,"median":-15.409236,"eighty":-15.203159,"marketCap":45913085},{"date":"2024-03-15","current":-13.270815,"twenty":-17.820809,"median":-15.409236,"eighty":-15.057448,"marketCap":33391335},{"date":"2024-03-22","current":-12.856102,"twenty":-17.518661,"median":-15.34438,"eighty":-13.839564,"marketCap":32347855},{"date":"2024-03-28","current":-9.656887,"twenty":-17.423869,"median":-15.187199,"eighty":-12.785008,"marketCap":24298158},{"date":"2024-04-05","current":-11.26226,"twenty":-17.423869,"median":-15.107401,"eighty":-12.559878,"marketCap":28563716},{"date":"2024-04-12","current":-10.85589,"twenty":-17.252059,"median":-14.262796,"eighty":-11.529063,"marketCap":27533066},{"date":"2024-04-19","current":-8.940145,"twenty":-16.820909,"median":-13.270815,"eighty":-10.646899,"marketCap":22674290},{"date":"2024-04-26","current":-8.185457,"twenty":-16.072132,"median":-12.878911,"eighty":-10.171589,"marketCap":20760226},{"date":"2024-05-03","current":-8.011298,"twenty":-15.61915,"median":-12.441389,"eighty":-9.218799,"marketCap":20318519},{"date":"2024-05-10","current":-6.676082,"twenty":-15.409236,"median":-11.944081,"eighty":-8.208678,"marketCap":16932099},{"date":"2024-05-17","current":-6.559976,"twenty":-15.406992,"median":-11.26226,"eighty":-8.011298,"marketCap":16637628},{"date":"2024-05-24","current":-5.773123,"twenty":-15.356229,"median":-10.681731,"eighty":-7.83714,"marketCap":13841623},{"date":"2024-05-31","current":-6.030941,"twenty":-15.281507,"median":-10.409864,"eighty":-6.954736,"marketCap":14459767},{"date":"2024-06-07","current":-4.748738,"twenty":-15.235078,"median":-10.159255,"eighty":-6.68061,"marketCap":11385560},{"date":"2024-06-14","current":-2.25909,"twenty":-15.107401,"median":-9.656887,"eighty":-6.509425,"marketCap":5416387},{"date":"2024-06-21","current":-1.821847,"twenty":-15.007495,"median":-8.940145,"eighty":-6.069835,"marketCap":4368054},{"date":"2024-06-28","current":-1.912311,"twenty":-14.84161,"median":-8.707933,"eighty":-5.984352,"marketCap":4584951},{"date":"2024-07-05","current":-1.595686,"twenty":-14.277975,"median":-8.24351,"eighty":-5.773123,"marketCap":3825813},{"date":"2024-07-12","current":-1.228176,"twenty":-14.247617,"median":-8.069351,"eighty":-4.748738,"marketCap":2944671},{"date":"2024-07-15","current":-1.226291,"twenty":-14.24184,"median":-8.069351,"eighty":-4.719086,"marketCap":2940152},{"date":"2024-08-02","current":-1.013952,"twenty":-14.236062,"median":-8.040325,"eighty":-4.535268,"marketCap":2431048},{"date":"2024-08-09","current":-0.885794,"twenty":-13.839564,"median":-8.011298,"eighty":-2.310102,"marketCap":2123778},{"date":"2024-08-16","current":-0.654013,"twenty":-13.158247,"median":-7.83714,"eighty":-1.891957,"marketCap":2229214},{"date":"2024-08-23","current":-2.636712,"twenty":-12.954324,"median":-7.140505,"eighty":-1.844463,"marketCap":7260829},{"date":"2024-08-30","current":-2.420589,"twenty":-12.883473,"median":-6.744599,"eighty":-1.891957,"marketCap":6665683},{"date":"2024-09-06","current":-2.068131,"twenty":-12.832404,"median":-6.687402,"eighty":-1.924373,"marketCap":5695102},{"date":"2024-09-13","current":-1.60378,"twenty":-12.678367,"median":-6.559976,"eighty":-1.829704,"marketCap":4416400},{"date":"2024-09-20","current":-1.622429,"twenty":-12.393993,"median":-6.417311,"eighty":-1.725453,"marketCap":4467754},{"date":"2024-09-27","current":-1.758564,"twenty":-12.190139,"median":-6.030941,"eighty":-1.729099,"marketCap":4842634},{"date":"2024-10-04","current":-1.723131,"twenty":-12.057464,"median":-5.826769,"eighty":-1.723525,"marketCap":4745063},{"date":"2024-10-11","current":-1.770191,"twenty":-11.67976,"median":-5.685419,"eighty":-1.725453,"marketCap":4874653},{"date":"2024-10-18","current":-1.640939,"twenty":-11.355145,"median":-5.192459,"eighty":-1.725453,"marketCap":4518726},{"date":"2024-10-25","current":-4.541316,"twenty":-11.227428,"median":-4.704227,"eighty":-1.717164,"marketCap":12505622},{"date":"2024-10-31","current":-4.448525,"twenty":-11.088102,"median":-4.448525,"eighty":-1.723131,"marketCap":12250098},{"date":"2024-11-08","current":-3.853568,"twenty":-10.85589,"median":-4.424907,"eighty":-1.725101,"marketCap":10611741},{"date":"2024-11-15","current":-10.217961,"twenty":-11.088102,"median":-4.448525,"eighty":-1.726861,"marketCap":28137649},{"date":"2024-11-22","current":-5.605162,"twenty":-11.378366,"median":-4.622772,"eighty":-1.72898,"marketCap":37261342},{"date":"2024-11-29","current":-5.285991,"twenty":-11.285481,"median":-4.70795,"eighty":-1.736236,"marketCap":29010326},{"date":"2024-12-06","current":-5.244908,"twenty":-11.122934,"median":-4.743697,"eighty":-1.739542,"marketCap":28784857},{"date":"2024-12-13","current":-1.906243,"twenty":-10.902332,"median":-4.70795,"eighty":-1.744391,"marketCap":10461755},{"date":"2024-12-20","current":-1.478982,"twenty":-10.729812,"median":-4.535858,"eighty":-1.726509,"marketCap":8116878},{"date":"2024-12-27","current":-2.097767,"twenty":-10.58386,"median":-4.43215,"eighty":-1.724313,"marketCap":11512866},{"date":"2025-01-03","current":-2.13273,"twenty":-10.499069,"median":-4.417664,"eighty":-1.725805,"marketCap":11704747},{"date":"2025-01-10","current":-1.293623,"twenty":-10.455734,"median":-4.2029,"eighty":-1.723525,"marketCap":7099600},{"date":"2025-01-17","current":-0.870573,"twenty":-10.310323,"median":-4.062655,"eighty":-1.649339,"marketCap":4777839},{"date":"2025-01-24","current":-0.821625,"twenty":-10.217961,"median":-3.965464,"eighty":-1.627827,"marketCap":4509205},{"date":"2025-01-31","current":-0.695759,"twenty":-10.19009,"median":-3.820818,"eighty":-1.596315,"marketCap":3818433},{"date":"2025-02-07","current":-0.713241,"twenty":-10.159255,"median":-2.907717,"eighty":-1.573503,"marketCap":3914374},{"date":"2025-02-14","current":-0.62933,"twenty":-10.101202,"median":-2.636712,"eighty":-1.510537,"marketCap":3453859},{"date":"2025-02-21","current":-0.716737,"twenty":-9.74575,"median":-2.540899,"eighty":-1.377788,"marketCap":3933562},{"date":"2025-02-28","current":-0.562901,"twenty":-9.640801,"median":-2.437302,"eighty":-1.224909,"marketCap":3089285},{"date":"2025-03-07","current":-0.510457,"twenty":-9.079472,"median":-2.372103,"eighty":-1.030709,"marketCap":2801464},{"date":"2025-03-14","current":-0.335713,"twenty":-8.754375,"median":-2.239137,"eighty":-0.96912,"marketCap":1842442},{"date":"2025-03-21","current":-0.335643,"twenty":-8.503123,"median":-2.198781,"eighty":-0.896348,"marketCap":1842058},{"date":"2025-03-28","current":-0.267465,"twenty":-8.285192,"median":-2.14239,"eighty":-0.857987,"marketCap":1467890},{"date":"2025-04-04","current":-0.24439,"twenty":-8.197068,"median":-2.097767,"eighty":-0.804927,"marketCap":1341248},{"date":"2025-04-11","current":-0.269213,"twenty":-8.092572,"median":-2.074831,"eighty":-0.719534,"marketCap":1477484},{"date":"2025-04-17","current":-0.137942,"twenty":-8.069351,"median":-2.037496,"eighty":-0.697857,"marketCap":1145530},{"date":"2025-04-25","current":-0.719207,"twenty":-8.034519,"median":-1.993365,"eighty":-0.682473,"marketCap":5972602},{"date":"2025-05-02","current":-0.577828,"twenty":-8.011298,"median":-1.936658,"eighty":-0.655985,"marketCap":4798528},{"date":"2025-05-09","current":-0.472927,"twenty":-8.011298,"median":-1.906243,"eighty":-0.642767,"marketCap":3927389},{"date":"2025-05-16","current":-0.378199,"twenty":-7.976467,"median":-1.862996,"eighty":-0.625834,"marketCap":3140728},{"date":"2025-05-23","current":-0.254249,"twenty":-7.883582,"median":-1.835754,"eighty":-0.593155,"marketCap":2824879},{"date":"2025-05-30","current":-0.250375,"twenty":-7.83714,"median":-1.821847,"eighty":-0.577167,"marketCap":2781833},{"date":"2025-06-06","current":-0.207274,"twenty":-7.721034,"median":-1.77581,"eighty":-0.547912,"marketCap":2302949},{"date":"2025-06-13","current":-0.273488,"twenty":-7.384327,"median":-1.751459,"eighty":-0.512702,"marketCap":3038630},{"date":"2025-06-20","current":-0.399633,"twenty":-7.094063,"median":-1.745839,"eighty":-0.507659,"marketCap":4440184},{"date":"2025-06-27","current":-0.371137,"twenty":-6.877648,"median":-1.738983,"eighty":-0.492098,"marketCap":4123580},{"date":"2025-07-01","current":-0.334649,"twenty":-6.816356,"median":-1.733515,"eighty":-0.475509,"marketCap":3718171}],"updateTime":1751515050684}}}